FDA approves Glenmark’s Emend generic
SILVER SPRING, Md. — The Food and Drug Administration has approved Glenmark Pharmaceuticals’ generic Emend (aprepitant) capsules. The drug is indicated to prevent nausea and vomiting in patients undergoing chemotherapy.
Glenmark’s generic will be available in 40-, 80- and 125-mg dosage strength capsules. The product had branded and generic U.S. sales of approximately $64.9 million for the 12 months ended August 2017, according to QuintilesIMS data.